Zevra Therapeutics to Report Fourth Quarter and Full-Year

Zevra Therapeutics to Report Fourth Quarter and Full-Year

CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare......

Zevra Therapeutics Announces Arimoclomol Research Featured

Zevra Therapeutics Announces Arimoclomol Research Featured

Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of......

CORRECTION – KemPharm Announces Corporate Name Change to

CORRECTION – KemPharm Announces Corporate Name Change to

New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community Branding reflects Company’s commitment to......

KemPharm Enhances Senior Management Team

KemPharm Enhances Senior Management Team

Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal Affairs CELEBRATION,......

menu
menu